We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approved 100th ANDA in 2021 for Originator Drugs With Inadequate Generic Competition
FDA Approved 100th ANDA in 2021 for Originator Drugs With Inadequate Generic Competition
The FDA approved the 100th abbreviated new drug application (ANDAs) through its congressionally established Competitive Generic Therapy (CGT) pathway in 2021, bringing new low-priced medicines to the market for originator drugs that the agency had deemed to have inadequate generic competition.